AI assistant
IMMUNIC, INC. — Director's Dealing 2018
Jun 11, 2018
10196_dirs_2018-06-11_a2f70d42-8015-47d9-b1fd-24483b1c3d7c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VITAL THERAPIES INC (VTL)
CIK: 0001280776
Period of Report: 2018-06-09
Reporting Person: DUNN JOHN MICHAEL (General Counsel and Secretary)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-06-09 | Stock Option (right to buy) | $5.0 | A | 45000 | Acquired | 2028-06-08 | Common Stock (45000.0) | Direct |
Footnotes
F1: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).